Interventional Radiology Imaging

What is the Best Initial Therapy for Uterine Fibroids in Patients Desiring Pregnancy?

·
What is the Best Initial Therapy for Uterine Fibroids in Patients Desiring Pregnancy?

A 34-year-old patient is in your office to discuss her treatment options. She and her partner have been trying to conceive for 18 months without success. An initial workup, including a transvaginal ultrasound, confirmed the presence of several uterine fibroids, with at least one appearing to indent the endometrial cavity. Her primary goal is to become pregnant, and she is seeking the best initial therapeutic step to manage her fibroids in a way that preserves or enhances her fertility. This scenario requires a careful selection of therapy to address the uterine pathology while optimizing the chances for a future successful pregnancy. According to the American College of Radiology (ACR) Appropriateness Criteria, for a reproductive-age patient with uterine fibroids desiring pregnancy and experiencing reproductive dysfunction, Hysteroscopic myomectomy is a ‘Usually appropriate’ initial therapy.

Who Fits This Clinical Scenario for Fibroid Management?

This guidance is specifically for reproductive-age patients with diagnosed uterine fibroids who are actively attempting to conceive and are experiencing reproductive dysfunction. This dysfunction can manifest as infertility (inability to conceive after 12 months of unprotected intercourse, or 6 months if over age 35) or recurrent pregnancy loss. The key elements defining this scenario are the patient’s explicit desire for future pregnancy and the clinical context of initial therapy, meaning no prior surgical or interventional fibroid treatments have been performed.

This workflow is not intended for:

  • Patients whose primary symptoms are bulk-related or heavy uterine bleeding. While these patients may also desire pregnancy, the therapeutic algorithm may differ if reproductive dysfunction is not the leading issue. A different set of considerations applies when the main goal is symptom relief.
  • Postmenopausal patients. The risks, benefits, and goals of treatment change significantly after menopause, and fertility preservation is no longer a factor.
  • Patients who do not desire future fertility. For these individuals, a wider range of therapies, including those that are not uterus-sparing (like hysterectomy) or have uncertain effects on pregnancy (like uterine artery embolization), become more viable options.
  • Patients with known concurrent adenomyosis. The presence of adenomyosis complicates the management strategy and may alter the effectiveness of fibroid-directed therapies.

What Diagnoses Are You Working Up in This Scenario?

While uterine fibroids are the known diagnosis, the therapeutic intervention in this context serves to both treat the fibroids and definitively evaluate the endometrial cavity for other potential causes of reproductive dysfunction. The goal is to address any structural abnormalities that could interfere with embryo implantation or fetal development.

Submucosal or Intramural Fibroids with Cavity Distortion: This is the primary therapeutic target. Fibroids that protrude into or distort the endometrial cavity (FIGO types 0, 1, and 2) are most strongly associated with infertility and pregnancy loss. They are thought to interfere with implantation by creating an irregular surface, causing local inflammation, or altering uterine contractility. The intervention aims to resect these specific fibroids to restore a normal uterine cavity.

Endometrial Polyps: These are common, benign growths within the uterine cavity that can mimic the appearance of small submucosal fibroids on ultrasound. Like fibroids, they can impair fertility by acting as a space-occupying lesion or inducing an inflammatory response. Hysteroscopy is the gold standard for both diagnosing and treating endometrial polyps, often at the same time as a myomectomy.

Intrauterine Adhesions (Asherman’s Syndrome): Though less common, scar tissue within the uterine cavity can cause infertility or recurrent miscarriages. A history of uterine surgery (including D&C or prior myomectomy) or endometritis increases this risk. Hysteroscopy is the definitive method for diagnosing and lysing these adhesions, restoring the cavity’s normal volume and function.

Congenital Uterine Anomalies: Anatomic variations like a uterine septum can coexist with fibroids and independently contribute to poor reproductive outcomes. Direct visualization via hysteroscopy allows for accurate diagnosis and, in the case of a uterine septum, concurrent surgical correction (septoplasty).

Why Is Hysteroscopic Myomectomy a ‘Usually Appropriate’ Initial Therapy?

For a patient desiring pregnancy, the ideal intervention directly addresses the pathology most likely to be interfering with implantation—the intracavitary fibroids—while minimizing trauma to the rest of the uterus. Hysteroscopic myomectomy achieves this precisely, which is why it, along with laparoscopic or open myomectomy, is rated ‘Usually appropriate’ by the ACR.

The procedure allows for direct visualization and resection of submucosal (FIGO type 0 and 1) and some intramural fibroids with an intracavitary component (FIGO type 2). By removing the lesion under direct sight, the surgeon can restore the normal contour of the endometrial cavity, which is critical for successful embryo implantation. It is a minimally invasive, uterus-sparing procedure with a relatively quick recovery time, allowing patients to resume attempts at conception within a few months.

In contrast, other therapies are rated lower for this specific clinical goal:

  • Uterine Artery Embolization (UAE) is rated ‘May be appropriate’. While highly effective for treating bleeding and bulk symptoms, its role in patients actively pursuing pregnancy is debated. There are concerns that embolization could compromise blood flow to the endometrium or ovaries, potentially affecting ovarian reserve and future placental function. Given these uncertainties, a direct surgical approach is often favored as the initial therapy for fertility.
  • Hysterectomy is rated ‘Usually not appropriate’. This is a definitive treatment for fibroids but results in the removal of the uterus, permanently ending the patient’s ability to carry a pregnancy. It is therefore contraindicated in any patient desiring future fertility.

All myomectomy approaches, as well as MR-guided focused ultrasound, are procedures that do not use ionizing radiation, so there are no associated radiation dose concerns. The decision between hysteroscopic and laparoscopic/open myomectomy depends on the fibroid’s location, size, and number, which must be carefully assessed with pre-procedural imaging, typically pelvic MRI or saline-infusion sonohysterography (SIS). This detailed mapping is crucial for surgical planning and determining if a purely hysteroscopic approach is feasible and safe.

What’s Next After Myomectomy? Downstream Fertility Workflow

The post-procedure workflow is centered on uterine healing and subsequent attempts at conception. The pathway depends on the surgical findings and the patient’s broader fertility profile.

If hysteroscopic myomectomy is successful: Following the complete resection of cavity-distorting fibroids, the patient is typically advised to wait for a period of 2 to 3 months to allow the endometrium to heal fully. Some surgeons may place a temporary intrauterine balloon or prescribe hormonal therapy to prevent adhesion formation. After this healing period, the couple can resume attempts at natural conception. If there are other coexisting factors for infertility (e.g., male factor, ovulatory dysfunction), a referral to a reproductive endocrinologist for assisted reproductive technology (ART) may be the most appropriate next step.

If fibroids are not amenable to hysteroscopy alone: If pre-procedural imaging or the hysteroscopy itself reveals large intramural or subserosal fibroids that cannot be addressed from within the cavity, the patient may require a second-stage procedure. This typically involves a laparoscopic or open myomectomy, another ‘Usually appropriate’ option. The goal remains the same: remove problematic fibroids while meticulously reconstructing the uterus to support a future pregnancy.

If the procedure is negative or reveals other pathology: If hysteroscopy shows a normal cavity or identifies and treats an alternative issue like a polyp or small septum, the focus shifts. The workup for other causes of infertility should be completed. This includes assessing ovulatory function, tubal patency (hysterosalpingogram), and male factor analysis. The patient has effectively had uterine-factor infertility ruled out or treated, and the investigation must continue elsewhere.

Pitfalls to Avoid (and When to Get Help)

Navigating fibroid management in the context of fertility requires careful planning to avoid common pitfalls. One major error is proceeding to therapy without adequate pre-procedural imaging. A standard 2D ultrasound may not sufficiently characterize the fibroid’s size, exact location, and degree of intramural extension; a pelvic MRI or saline-infusion sonohysterography is often essential for proper surgical planning. Another pitfall is failing to set realistic expectations about the impact of myomectomy on fertility, as success is not guaranteed and depends on many other factors. Finally, it’s crucial to avoid recommending therapies like endometrial ablation or hysterectomy, which are ‘Usually not appropriate’ as they would preclude future pregnancy. If the fibroid burden is extensive or involves difficult locations (e.g., near the cornua or cervix), referral to a surgeon with advanced expertise in complex myomectomy is the appropriate escalation.

Related ACR Topics and Tools

The ACR Appropriateness Criteria provide evidence-based guidance for a wide range of clinical scenarios. For a comprehensive overview of all variants related to uterine fibroids, including management for bulk symptoms or in postmenopausal patients, please consult our parent guide. Additional GigHz tools can assist in applying these standards to your practice.

Frequently Asked Questions

Why is laparoscopic or open myomectomy also rated ‘Usually appropriate’ for this scenario?

Laparoscopic or open myomectomy is also rated ‘Usually appropriate’ because it is necessary for fibroids that are not accessible hysteroscopically. This includes intramural fibroids that do not significantly indent the cavity and subserosal fibroids. The choice between hysteroscopic and laparoscopic/open approaches is determined by the fibroid’s location and size, with the goal always being to remove the problematic fibroid while preserving uterine integrity for future pregnancy.

If a patient has both heavy bleeding and a desire for pregnancy, does this guidance still apply?

Yes, but with added complexity. If a patient has both symptoms, a myomectomy (hysteroscopic or otherwise) remains a ‘Usually appropriate’ choice as it can address both the bleeding (by removing the fibroid) and the infertility. However, the urgency and approach might be tailored. The key is that the desire for pregnancy rules out definitive treatments like hysterectomy or endometrial ablation.

What is the role of medical management for this specific patient?

Medical management (e.g., GnRH agonists) is rated ‘May be appropriate (Disagreement)’ by the ACR for this scenario. While hormonal therapies can shrink fibroids and control bleeding, they also prevent conception while in use. They are sometimes used as a short-term preoperative measure to reduce fibroid size and vascularity before a myomectomy, but they are not a primary long-term solution for a patient actively trying to conceive.

How soon after a myomectomy can a patient attempt to get pregnant?

The recommended waiting period varies based on the type and extent of the surgery. After a hysteroscopic myomectomy, the wait is typically shorter, around 2-3 months. After a laparoscopic or open myomectomy that involves a deep incision into the uterine wall, surgeons often recommend waiting 3-6 months to allow for adequate healing and to reduce the risk of uterine rupture during a future pregnancy.

Does MR-guided high-frequency focused ultrasound (MRgFUS) have a role here?

MR-guided high-frequency focused ultrasound (MRgFUS) is rated ‘May be appropriate’. It is a non-invasive thermal ablation technique. While it preserves the uterus, there is less data on its long-term effects on endometrial function and pregnancy outcomes compared to myomectomy. For this reason, myomectomy is often preferred as the initial, more established therapy for patients whose primary goal is achieving pregnancy.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026